KIF21B

Across TCGA pan-cancer cohorts, KIF21B Mutation is linked to patient survival in 8 of 34 cancer types, making it a survival-associated KIF21B data layer compared with 22 for mass-spec protein and 4 for mass-spec protein.

The strongest signal is observed in uterine corpus endometrial carcinoma (UCEC), where higher KIF21B Mutation is associated with better disease-free survival. In most high-consensus cancer types, elevated KIF21B expression acts as an unfavorable survival marker, although some lineages such as UCEC and STAD show a favorable association.

UCEC, HNSC, and STAD are the cancer types where KIF21B Mutation most reproducibly stratifies survival.

Mutation survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
UCEC	DFS	Median	All	0.794	0.625	<.001	36	view →
HNSC	OS	Median	II,III,IV	0.526	0.747	.013	17	view →
STAD	DFS	Median	All	0.872	0.372	.008	13	view →
LIHC	OS	Median	All	0.098	0.774	.001	6	view →
MESO	OS	Median	All	0.169	0.556	.043	3	view →
LGG	OS	Median	All	0.270	0.799	.003	3	view →
ACC	DFS	Median	All	0.195	0.748	.003	3	view →
SKCM	DFS	Median	All	0.789	0.608	.032	2	view →

Pink = unfavorable, green = favorable. Showing the 8 strongest of 8 lineages.

KIF21B–UCEC (DFS)

Open the UCEC breakdown →